NCT04573725View on ClinicalTrials.gov

Early Phase 2 Clinical Study of TS-142 in Patients with Insomnia Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 7, 2017

Primary Completion Date

February 13, 2019

Study Completion Date

February 13, 2019

Conditions
Insomnia Disorder
Interventions
DRUG

TS-142

Participants received single-dose of 5, 10, 30 mg of TS-142 (oral capsule)

DRUG

Dose-matched Placebo to TS-142

Participants received single dose-matched placebo to TS-142 (oral capsule)

Trial Locations (1)

Unknown

Taisho Pharmaceutical Co., Ltd selected site, Tokyo

All Listed Sponsors
lead

Taisho Pharmaceutical Co., Ltd.

INDUSTRY

NCT04573725 - Early Phase 2 Clinical Study of TS-142 in Patients with Insomnia Disorder | Biotech Hunter | Biotech Hunter